Results of a new study show that IsoPSA, a novel prostate-specific antigen assay, is readily adopted by practitioners in various practice settings, and its use significantly reduces biopsies in men being evaluated for elevated PSA.
For select patients, high-intensity focused ultrasound, a type of focal therapy for treating localized prostate cancer, may be an attractive alternative to more traditional treatments, such as surgery and radiation.
A new Cleveland Clinic study documents the impacts that shortages of the immunotherapy agent Bacillus Calmette-Guerin have had on clinical management of non-muscle invasive bladder cancer. Urologic oncologist Robert Abouassaly, MD, discusses the findings and implications.
Urologist Robert Abouassaly, MD, MSc, says the specialty continues to shift the risk-benefit ratio in favor of the patient.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Urologists develop novel evidence-based hospital quality scoring system, the Bladder Cancer Quality Score (BC-QS). They hope it serves as a foundation for continued efforts to improve surgical quality measurement and outcomes.
Though the wait is on for the data to mature, apalutamide could lead to survival improvement in a significant number of patients and a major impact on treatment of patients with M0CRPC.